Back to top

Image: Bigstock

Are Investors Undervaluing Jazz Pharmaceuticals (JAZZ) Right Now?

Read MoreHide Full Article

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.

Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.

Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.

Jazz Pharmaceuticals (JAZZ - Free Report) is a stock many investors are watching right now. JAZZ is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value.

Value investors also use the P/S ratio. The P/S ratio is is calculated as price divided by sales. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. JAZZ has a P/S ratio of 4.15. This compares to its industry's average P/S of 5.7.

Finally, our model also underscores that JAZZ has a P/CF ratio of 9.77. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. JAZZ's P/CF compares to its industry's average P/CF of 15.01. Over the past 52 weeks, JAZZ's P/CF has been as high as 12.20 and as low as 7.53, with a median of 9.84.

Value investors will likely look at more than just these metrics, but the above data helps show that Jazz Pharmaceuticals is likely undervalued currently. And when considering the strength of its earnings outlook, JAZZ sticks out at as one of the market's strongest value stocks.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Jazz Pharmaceuticals PLC (JAZZ) - free report >>

Published in